Peskin Pharmaceuticals® follows the new medicament paradigm. Instead of treating diseases / disorders by blocking / impeding and “managing” the illness’ progression, our focus is reversing and optimizing the resolution of the underlying disease / disorder.
We are currently investigating chronic inflammation — the cornerstone — of many diseases/disorders. Compensating for an impaired delta-6 desaturase metabolic pathway is fundamental and required to successfully reverse the underlying etiology of these diseases. Once inflammation is reduced, healing accelerates, naturally. We are in the forefront of this groundbreaking science.
Based on over 25 years of state-of-the-art medical research, our mission as “The green drug company” is to bring to market drugs that serve the patient utilizing state-of-the-art lipid physiology as well as the environment, by using an eco-friendly approach. We specialize in a new class of drug; derived from natural, unadulterated lipid sources in unique ways; not chemically synthesized. The significant benefit is lack of negative side-effects.
Our unique focus is compensating for an impaired Δ-6 Desaturase metabolic pathway to decrease inflammation. This pathway is impaired in numerous patient populations. EZtrektm is our new Medical Food that we released in the fourth quarter of 2021.
EZTREK™ Medical Food: After twenty years in development, it is the 1st Medical Food designed to compensate for impaired delta-6 desaturase (D6D) metabolic pathways. Many patient populations suffer from this impairment leading to chronic systemic inflammation. Our goal is to introduce the medical community to EZTREK™ for the treatment of systemic inflammation that is a part of many intractable diseases.